STOCK TITAN
  1. Home
  2. Sec-filings
  3. URGN
  4. [144] UroGen Pharma Ltd. SEC Filing

UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

UroGen Pharma Ltd. (symbol URGN) received a Form 144 notice indicating that officer Mark Schoenberg plans sales of common shares under Rule 144, with RBC Capital Markets LLC as the broker. The common stock is listed on Nasdaq. The shares to be sold were acquired through a stock option exercise from the issuer on January 27, 2023. Over the prior three months, Schoenberg reported two Rule 144 sales of UroGen common stock totaling 20,000 shares, for gross proceeds of $400,008.00 on July 9, 2026 and $350,143.00 on June 22, 2026.

Positive

  • None.

Negative

  • None.
Shares sold June 22, 2026 10,000 shares UroGen Pharma common stock sold by Mark Schoenberg on June 22, 2026
Proceeds June 22, 2026 sale $350,143.00 Gross proceeds for 10,000 UroGen Pharma shares sold June 22, 2026
Shares sold July 9, 2026 10,000 shares UroGen Pharma common stock sold by Mark Schoenberg on July 9, 2026
Proceeds July 9, 2026 sale $400,008.00 Gross proceeds for 10,000 UroGen Pharma shares sold July 9, 2026
Total shares sold past 3 months 20,000 shares Cumulative UroGen Pharma shares sold by Mark Schoenberg in the past three months
Acquisition date of shares to be sold 01/27/2023 Date of stock option exercise through which the shares were acquired from the issuer
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
stock option exercise financial
"01/27/2023 | STOCK OPTION EXERCISE | ISSUER"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
securities to be sold financial
"144: Securities To Be Sold"
securities sold during the past 3 months financial
"144: Securities Sold During The Past 3 Months"

FAQ

What does UroGen Pharma Ltd. (URGN) disclose in this Form 144?
The filing reports that officer Mark Schoenberg intends to sell UroGen Pharma common stock under Rule 144 through RBC Capital Markets LLC, with the shares having been acquired via a stock option exercise on January 27, 2023.

How many URGN shares has Mark Schoenberg sold recently under Rule 144?
Over the past three months, Mark Schoenberg reported sales totaling 20,000 shares of UroGen Pharma common stock, consisting of 10,000 shares sold on June 22, 2026 and 10,000 shares sold on July 9, 2026.

What proceeds did Mark Schoenberg receive from recent URGN stock sales?
The reported gross proceeds from recent sales were $350,143.00 for 10,000 shares on June 22, 2026 and $400,008.00 for 10,000 shares on July 9, 2026, both involving UroGen Pharma Ltd. common stock.

How were the URGN shares to be sold originally acquired by Mark Schoenberg?
The shares covered by this notice were acquired through a stock option exercise from the issuer, UroGen Pharma Ltd., on January 27, 2023, as indicated in the securities-to-be-sold section of the filing.

Which broker is handling the planned URGN stock sales for this Form 144?
The planned sales of UroGen Pharma Ltd. common stock are associated with RBC Capital Markets LLC, based in Minneapolis, which is listed as the broker in the securities information and sales history sections.

Where is UroGen Pharma Ltd. (URGN) headquartered according to this filing?
UroGen Pharma Ltd. is based in Ra’anana, Israel, at 9 Ha'Ta'asiya Street, with a listed telephone number of +972 9 770 7601, reflecting its Israeli corporate headquarters information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR